Navigation Links
Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City

BASKING RIDGE, N.J., Feb. 23, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be speaking and participating on a panel that will highlight new and innovative cardiovascular drug therapies at the 2011 RBC Capital Markets Healthcare Conference.  The panel discussion will be held at the New York Palace Hotel in New York City on Wednesday, March 2, 2011 at 2:35 p.m. EST in Holmes 1.  


Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.


Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at


Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the active control agent of pegnivacogin.  

More information can be found at www.regadobio.comContact:  Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.comMedia Contact:Tiberend Strategic Advisors, Inc.1-212-827-0020Andrew Mielach,

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
(Date:11/24/2015)... -- The hope of bearing a child ... cycles. After failure of over 15 IVF cycles, Mrs. ... hopes that she would be able to conceive ever. But finally optimism prevailed as she ... of over 15 IVF cycles. India ... one last attempt with Gaudium IVF Center in New ...
(Date:11/24/2015)...  Thanks to a donor with a personal connection ... Sister Diane Grassilli Center for Women,s Health now offers ... San Francisco . Fred Ruhland ... a gift of $617,320 that allowed the Center to ... and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography for ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... ) has focused on providing comprehensive solutions involving adult stem cell therapies to ... has officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software helps practice ... an agreement between the practice owner and the patient that automatically manages all ... projections. Click here to learn more. , According to ...
(Date:11/24/2015)... ... 2015 , ... New patients who wish to seek treatment for missing teeth ... at her Mississauga, ON practice. Dr. Williams has been providing dental service for over ... , Missing teeth can lead to a variety of complications if they are not ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):